Key result
Acute cardiac contractility modulation stimulation significantly increased peak contractile force by 43% in 3D engineered cardiac tissues, whereas conventional 2D monolayers displayed no contractile response.
Why the study?
The authors sought to extend previous 2D and animal findings to human 3D microphysiological systems to develop a robust model to evaluate clinical CCM pulse parameters in vitro.
Does acute cardiac contractility modulation (CCM) stimulation improve contractile properties in 3D human engineered cardiac tissues compared to 2D monolayers?
Does acute cardiac contractility modulation (CCM) stimulation improve contractile properties in 3D human engineered cardiac tissues compared to 2D monolayers?
Absolute Event Rate: 43% vs -1%
p-value: p=<0.05
3D human engineered cardiac tissues provide a robust in vitro model for evaluating the acute contractile effects of cardiac contractility modulation, unlike conventional 2D monolayers on stiff substrates.
CCM effects in advanced in vitro models are preliminary; leaves open clinical translation and device optimization.
Cardiac contractility modulation (CCM) is a medical device therapy whereby non-excitatory electrical stimulations are delivered to the myocardium during the absolute refractory period to enhance cardiac function. We previously evaluated the effects of the standard CCM pulse parameters in isolated rabbit ventricular cardiomyocytes and 2D human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) monolayers, on flexible substrate. In the present study, we sought to extend these results to human 3D microphysiological systems to develop a robust model to evaluate various clinical CCM pulse parameters in vitro . HiPSC-CMs were studied in conventional 2D monolayer format, on stiff substrate (i.e., glass), and as 3D human engineered cardiac tissues (ECTs). Cardiac contractile properties were evaluated by video (i.e., pixel) and force-based analysis. CCM pulses were assessed at varying electrical ‘doses’ using a commercial pulse generator. A robust CCM contractile response was observed for 3D ECTs. Under comparable conditions, conventional 2D monolayer hiPSC-CMs, on stiff substrate, displayed no contractile response. 3D ECTs displayed enhanced contractile properties including increased contraction amplitude (i.e., force), and accelerated contraction and relaxation slopes under standard acute CCM stimulation. Moreover, 3D ECTs displayed enhanced contractility in a CCM pulse parameter-dependent manner by adjustment of CCM pulse delay, duration, amplitude, and number relative to baseline. The observed acute effects subsided when the CCM stimulation was stopped and gradually returned to baseline. These data represent the first study of CCM in 3D hiPSC-CM models and provide a nonclinical tool to assess various CCM device signals in 3D human cardiac tissues prior to in vivo animal studies. Moreover, this work provides a foundation to evaluate the effects of additional cardiac medical devices in 3D ECTs.
No takes yet. Share an insight, caveat, or question.
Feaster et al. (2022) studied Healthy cardiomyocyte models (evaluating CCM for Heart Failure). Cardiac contractility modulation (CCM) stimulation vs. Baseline (field stimulation pacing at 1 Hz) was evaluated on Change in peak contractile amplitude/force from baseline (p=<0.05). Acute cardiac contractility modulation stimulation significantly increased peak contractile force by 43% in 3D engineered cardiac tissues, whereas conventional 2D monolayers displayed no contractile response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: